NCT06667024View on ClinicalTrials.gov

Dexmedetomidine as an Intrathecal Adjuvant to Hyperbaric Bupivacaine for Postoperative Analgesia in Patients Undergoing Arthroscopic Anterior Cruciate Ligament Reconstruction Surgeries

NACompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

April 30, 2024

Study Completion Date

April 30, 2024

Conditions
DexmedetomidineIntrathecalAdjuvantHyperbaric BupivacaineAnalgesiaArthroscopic Anterior Cruciate Ligament Reconstruction
Interventions
DRUG

Hyperbaric bupivacaine

Patients received the standard spinal anesthesia with 0.5% 3 ml according to the patient hyperbaric bupivacaine only

DRUG

Dexmedetomidine and Hyperbaric bupivacaine

Patients received dexmedetomidine 4 μg and 0.5% (3-4 ml according to the patient height) hyperbaric bupivacaine

Trial Locations (1)

31527

Tanta University, Tanta

All Listed Sponsors
lead

Tanta University

OTHER

NCT06667024 - Dexmedetomidine as an Intrathecal Adjuvant to Hyperbaric Bupivacaine for Postoperative Analgesia in Patients Undergoing Arthroscopic Anterior Cruciate Ligament Reconstruction Surgeries | Biotech Hunter | Biotech Hunter